OUP publishes first issue of ESC's European Heart Journal - Cardiovascular Pharmacotherapy

NewsGuard 100/100 Score

Oxford University Press (OUP) is delighted to announce the publication of the first issue of European Heart Journal - Cardiovascular Pharmacotherapy (EHJCVP), which it is publishing on behalf of the European Society for Cardiology (ESC) and the Working Group on Cardiovascular Pharmacotherapy.

Pharmacotherapy is an increasingly important area of cardiology given the high number of cardiac patients who are on medication of some kind. This new journal aims to publish the highest quality research, interpreting and integrating new scientific developments within the field of cardiovascular pharmacotherapy.  The overarching goal of the journal is to improve the care of patients with cardiovascular disease with a specific focus on cardiovascular pharmacotherapy.

Professor Fausto Pinto, President of the ESC said: "The ESC is very proud to launch this new journal that will address a gap in cardiovascular publications today. Updated information on new treatment strategies is essential for today's practices and better patient management. I am certain that this new member of the ESC journal family will be very useful and well received by the cardiovascular community."

Helen Leipman, Senior Publisher at OUP said: "Oxford University Press is very proud to be involved in this new initiative of the ESC as publisher of their new journal. The field of clinical cardiovascular pharmacology is a burgeoning one but it is ever important to focus on improving prognosis for cardiovascular disease and we hope that we can go some way to achieving that with the new journal. Alongside European Heart Journal and Cardiovascular Research, EHJ-Cardiovascular Pharmacotherapy is an important addition to the ESC journal family and we look forward to working with Professor Agewall and his team to make it a great success."

Source:

Oxford University Press

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Revolutionizing heart failure treatment: Advances in mechanical circulatory support devices